Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects | Zendy

Kim van der Zander | Zendy; Michiel L. Bots | Zendy; Annette Bak | Zendy; M.M.G. Koning | Zendy; Peter W. de Leeuw | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects

Author(s) -

Kim van der Zander,

Michiel L. Bots,

Annette Bak,

M.M.G. Koning,

Peter W. de Leeuw

Publication year - 2008

Publication title -

american journal of clinical nutrition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.608

H-Index - 336

eISSN - 1938-3207

pISSN - 0002-9165

DOI - 10.3945/ajcn.2008.26003

Subject(s) - blood pressure , placebo , medicine , urinalysis , hematocrit , creatinine , excretion , urine , endocrinology , pathology , alternative medicine

Several placebo-controlled clinical studies suggest that products containing isoleucyl-prolyl-proline and valyl-prolyl-proline are able to lower blood pressure without adverse effects. The most efficient way of producing high concentrations of these lactotripeptides (LTPs) is enzymatic hydrolysis of dairy protein (casein) with the use of a mixture of several enzymes derived from the nongenetically modified organism Aspergillus oryzae, including proteases and peptidases. To date, no large studies of the blood pressure-lowering properties of enzymatically produced LTP (ELTP) powder in European populations have been published.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research